PRODUCT SECURITY AND COORDINATED VULNERABILITY DISCLOSURE PROCESS FOR DIAGNOSTIC PRODUCTS
At Leica Biosystems, we develop technologies to advance and optimize the laboratory. To achieve this, we uphold core values that define our responsibility to those we serve. Among them: an unwavering commitment to the safety and security of patients and laboratory personnel. Therefore, we believe in continuously improving to address the ever-evolving privacy and cybersecurity landscape.
In response to potential threats to cybersecurity, Leica Biosystems is part of a global product security team to assess vulnerabilities and determine responses within a Coordinated Vulnerability Disclosure (CVD) process. These efforts allow the company to continually learn from vulnerability test information submitted to us by customers and security researchers.
For the latest product detail information, please visit product security updates.
This CVD process applies to the reporting of potential cybersecurity vulnerabilities in Leica Biosystems products and services.
Contact information and CVD submission process
Potential security vulnerabilities or privacy issues with a Leica Biosystems product should be reported to:
Please use email encrypted with our public PGP key.
We ask that you please refrain from including sensitive information (e.g., sample information, PHI, PII, etc.) as a part of any submissions to Leica Biosystems. Please provide the following information in your submission:
- Your contact information (e.g., name, address, phone number)
- Date and method of discovery
- Description of potential vulnerability
- Product name
- Version number
- Configuration details
- Steps to reproduce
- Tools and methods
- Exploitation code
- Privileges required
- Results or impact
What happens next
Upon receipt of a potential product vulnerability submission, Leica Biosystems will:
- Acknowledge receipt of the submission within five (5) business days
- Work with specialized product teams to evaluate and validate reported findings
- Contact the submitter to request additional information, if needed
- Take appropriate action
Leica Biosystems considers it a top priority to protect the health and safety, as well as the personal information, of our customers' patients.
When conducting your security research, please avoid actions that could cause harm to patients or products. Note that vulnerability testing could negatively impact a product. As such, testing should not be conducted on active products in a clinical setting, and products subjected to security testing should not subsequently be used in a clinical setting. If there is any doubt, please contact a Leica Biosystems representative.
Leica Biosystems reserves the right to modify its coordinated vulnerability disclosure process at any time, without notice, and to make exceptions to it on a case-by-case basis. No level of response is guaranteed.
CAUTION: Do not include sensitive information (e.g., sample information, PHI, PII, etc.) in any documents submitted to Leica Biosystems. Comply with all laws and regulations during your testing activities.
Note: When sharing any information with Leica Biosystems, you agree that the information you submit will be considered non-proprietary and non-confidential and that Leica Biosystems can use such information in any manner, in whole or in part, without any restriction.